PGI58 Health Technology Assessment In Chronic Hepatitis C: Assessment of Decision Landscape And Manufacturer Inputs In Six Agencies  by Mazumder, D et al.
A632  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
PGI56
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Objectives: To describe the population of moderate-to-severe IBS-C patients in 
French clinical practice and to compare the main data with the European data from 
the IBIS-C study. The IBIS-C study was conducted in six European countries (France, 
Germany, Italy, Spain, Sweden and UK). MethOds: Observational, retrospective-
prospective (6 months each) study of patients diagnosed (Rome-III criteria) in the 
last five years and moderate-to-severe IBS-C severity at inclusion (IBS-Symptom 
Severity Scale [IBS-SSS] score ≥ 175). Healthcare resource utilisation (HRU) was ret-
rospectively and prospectively assessed and quality-of-life (QoL) was assessed at 
baseline with IBS-QoL and EuroQoL-5D (EQ-5D). Results: Patient characteristics 
were similar between the French (n= 59) and European (n= 525) cohorts: mean (±SD) 
age 47.7±15.7 and 45.3±15.8 years; 83% and 87% were female, and 63% and 60% had 
severe IBS-C. Mean symptom duration: 13.5±13.5 and 12.8±13.1 years; mean time 
since diagnosis: 2.6±6.3 and 3.0±5.2 years. At baseline, mean IBS-QoL was 42.9±19.0 
and 54.9±22.7 (scale: 0-100[worst-best]); mean EQ-5D was 46.6±22.2 and 55.5±21.7 
(scale: 0-100[worst-best]). Over follow-up, 76% French and 73% European patients 
consulted a GP (mean: 4.2 and 4.9 visits), and 100% and 92% a gastroenterologist 
(mean: 2.2 and 2.8 visits). 17% and 18% required emergency department visits/hos-
pitalisation (mean stay: 6±6 and 14±24 days). 51% and 65% of patients took prescrip-
tion drugs for their IBS-C, 61% and 67% took non-prescription drugs. Mean symptom 
severity (IBS-SSS) improved: 338.9±78.6 (baseline) to 281.5±102.1 (6 months) for the 
French cohort; 323.2±84.3 to 253.9±105.6 for the European cohort. The total mean 
(95%CI) annual cost for moderate-to-severe IBS-C was € 4,128 (2,262-6,633) for 
the French cohort; € 4,639 (3,733-5,598) for the European cohort. cOnclusiOns: 
Moderate-to-severe IBS-C symptoms in France were similar to those other European 
countries. QoL impairment and HRU were high for both cohorts. Moderate-to-severe 
IBS-C continued to be a burden for both cohorts with a high economic cost despite 
availability of therapeutic interventions.
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Objectives: To understand medical resource utilisation (MRU) of Australian 
patients with genotype 1 chronic hepatitis C (GT1 CHC) including those receiv-
ing current standard of care treatment (telaprevir or boceprevir with pegylated 
interferon and ribavirin). MethOds: Medical records were reviewed for a strati-
fied random sample of GT1 CHC patients first attending two liver clinics between 
2011 and 2013 (principal population; PP) supplemented by all GT1 CHC patients 
attending one transplant clinic in the same period (transplant population; TP). 
CHC-related MRU (percentage and annual rate [poisson] of outpatient, hospitali-
sation, laboratory and imaging tests) is reported for the PP by treatment status 
(treated/not treated) stratified by fibrosis grade; and for TP pre-transplant, year 
of transplant and post-transplant. Results: Comprehensive MRU was collected 
for 276 PP patients (F0-1 n= 59, F2 n= 58, F3 n= 53, F4 n= 106; 38 were treatment 
experienced prior to first visit; mean follow-up 17.6 months). Fifty-five (19.9%) 
received triple therapy. Data were collected for 112 TP patients (mean follow-up 
29.9 months), 33 (29.5%) received a transplant during the study and 51 (45.5%) 
beforehand. MRU was higher while treated including annual rates of outpatient 
visits (PP: 9.67 vs 2.91 [F0-1 2.60, F2 2.56, F3 2.63, F4 3.33]; TP: transplant 18.00 vs 
pre 5.55, post 5.14), psychiatric visits (PP: 0.71 vs 0.18 [F0-1 0.25, F2 0.16, F3 0.20, 
F4 0.14]; TP: transplant 0.00 vs pre 0.50, post 0.01), nurse visits (PP: 1.84 vs 0.42 
[F0-1 0.58, F2 0.42, F3 0.51, F4 0.32]); and the percentage with hospitalisation (PP: 
27.3% vs 13.0% [F0-1 3.4%, F2 10.3%, F3 9.4%, F4 21.7%]; TP: transplant 100% vs pre 
96.5%, post 79.2%). cOnclusiOns: CHC-related MRU increases substantially with 
disease severity. To our knowledge, these are the first real-world MRU reported 
for GT1 CHC in Australia and will be valuable in assessing the impact of new 
hepatitis C treatments.
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Objectives: To evaluate the landscape of health technology assessment (HTA) 
decisions for chronic hepatitis C (CHC) therapies in Canada (CADTH), Australia 
(PBAC), England and Wales (NICE), Scotland (SMC), Germany (IQWiG), and France 
(HAS). MethOds: Selected HTA agency websites were searched for submissions 
made in the CHC therapy area. Submissions were searched for following informa-
tion: clinical and economic input provided in the submission, recommendations 
from HTA agencies, and drivers of HTA decisions. Results: Victrelis®, Daklinza®, 
Roferon A®, Intron A®, Harvoni®, Viekirax®, Pegasys RBV®, PegIntron®, Rebetol®, 
Olysio®, Sovaldi®, and Incivo® were the pharmacotherapies for which manufac-
turer submissions were available across selected agencies. The number of HTA 
submissions with completion status ranged from 6-12. The percentage recommen-
dation ranged from 43% in Australia to 100% in France and Canada. The number 
of clinical studies supporting the manufacturer submission ranged from 2-12. The 
status, and treatment patterns. Physicians were screened for duration of prac-
tice (≥ 3yrs) and patient volume (≥ 15 HCV patients/mo) and recruited from a 
large panel to be geographically representative. Medical charts of the next 10 
consecutive HCV patients were abstracted. G1 HCV patient data was ana-
lyzed. Results: 2067 eligible G1 HCV patients were included in the analysis 
(France:374/Germany:506/Italy:412/Spain:475/UK:300). Patient characteristics 
included (France/Germany/Italy/Spain/UK) - mean age (yrs):53/49/55/52/45; male: 
61%/67%/61%/59%/69%; patient weight < = 80kg:81%/66%/83%/74%/76%; major-
ity were G1-subtype A (52%/44%/31%/34%/68%) or B (48%/54%/68%/66%/32%); 
any substance-abuse:23%/18%/10%/17%/47%; route of infection via intravenous 
drug use:55%/33%/31%/41%/69%, via blood transfusion:19%/26%/21%/36%/7%, 
via heterosexual contact:5%/11%/22%/11%/7%, via homosexual con-
tact:8%/13%/10%/6%/12%; current fibrosis scores were – F0:9%/18%/6%/7%/20%, 
F1:18%/30%/25%/25%/32%, F2:24%/28%/32%/24%/18%, F3:21%/17%/17%/20%/11%, 
F4:29%/6%/20%/23%/19%. In France/Germany/Italy/Spain/UK, latest mean alanine 
aminotransferase levels were:58/90/95/62/73; patients with undetectable (0-500) 
viral load (VL):5%/2%/25%/2%/1%; 501-< = 1Million VL-count:58%/39%/52%/75%; > 1M 
VL-count:38%/26%/38%/45%/25%. Treatment patterns included (France/Germany/
Italy/Spain/UK)- currently treated:23%/28%/20%/17%/20%, not currently treated 
(previous treatment non-responder, discontinued or relapsed, or therapy com-
plete and awaiting sustained viral response):21%/20%/29%/30%/22%, not current 
treated because patient achieved sustained viral response:19%/12%/11%/13%/6%; 
treatment naïve/never been treated:38%/40%/41%/41%/52%. cOnclusiOns: 
In this cohort of G1 HCV patients, treatment rates and disease burden varied 
among studied countries in EU; only a small proportion of patients had unde-
tectable VL or was not treated owing to achieving sustained viral response. 
Further research is warranted to assess the observed treatment patterns, effec-
tiveness of regimens, and patient management strategies to alleviate patient 
burden.
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Objectives: The analysis aimed to evaluate the evolution of the national and 
regional public expenditure regarding Proton Pump Inhibitors (PPIs) in Italy, in 
relation to national and regional policies. MethOds: The analysis combined 
data published by the Italian Medicines Agency (AIFA) and Regions and regional 
and national laws, to understand the impact of the applied policies on PPIs 
expenditure. Results: Over the past ten years, PPIs consumption increased 
by 280% (around 14% yearly), with lansoprazole reaching +533%. The number 
of patients ≥ 18 treatable with PPIs in 2013 was 2.873.500 (6% of adult popu-
lation), being the first class in terms of expenditure with a per capita value of 
15.2€ and consumptions of 74 DDD/1.000 inh./die. Consumptions and expenditure 
incresed by respectively 6.5% and 1.6% vs 2012. AIFA also highlighted a trend to 
prescriptive inappropiateness over the years, where the 46.5% of patients do not 
meet the reimbursability criteria by law. At regional level, Regions have issued 
a number of regional laws to contain both consumptions and expenditure (e.g. 
through reference pricing or guidelines to encourage the prescription of generi-
cated drugs), identifying specific performance indicators and target values. We 
estimated potential savings from the correct application of the reimburability 
criteria amounting to 260 million € /year, if Regions were able to control pre-
scriptive appropriateness, to which additional savings could be added through 
focused cost-containment measures. cOnclusiOns: Despite a number of 
efforts at both central and regional level, the trend towards inappropriateness 
and expenditure increase of PPIs is confirmed. A review of both national and 
regional policies on PPIs expenditure is key to reduce the current waste of eco-
nomic resources and, with a stable total budget, guarantee additional funding for 
innovation.
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Objectives: Comprehensive assessment of the financial costs of drug treatment of 
nonalcoholic steatohepatitis (NASH) in a hospital of Kharkiv, Ukraine. MethOds: 
For the study, the schemes medicinal histories of 54 patients with NASH in a hos-
pital in Kharkov during 2013 were used. The structure of costs of NASH treatment 
was assessed by the ABC analysis. Assessment of the level of NASH treatment cor-
respondence was conducted by the formal VEN analysis according to the National 
Drug Formulary (NDF) of Ukraine (2013). Index “V” was put in case of availability of 
the drug in the NDF, index “N” – in case of its absence. Directions of NASH treat-
ment were assessed by the prescriptions of drugs according to requirements of 
Ukrainian Cinical Guidelines (O.Ia. Babak, 2007) and according to Practice Guideline 
by the American Association for the Study of Liver Diseases (AASLD) for 2012. In 
determining the cost of drugs, their prices as of May 2015 by the data of Morion 
reference and retrieval system “Drugs” were used. Results: Drug treatment of 
patients with NASH by pharmacotherapeutic groups met the basic requirements 
of Ukrainian Clinical Guidelines and Guidelines of American scientists AASLD, 
which confirms the rationality of prescriptions. According to the ABC/VEN analy-
sis, most of the funds for treatment (82%) were spent on 76% of drugs included in 
the NDF. But 24% of drugs were missing from the NDF of Ukraine, indicating the 
need to correct NASH treatment in the hospital of Ukraine. cOnclusiOns: 76% 
of drugs prescribed to patients with NASH can be considered rational, but 24% of 
drugs had index “N”, indicating their inappropriate use. Comparison of the ABC 
and VEN analysis showed the need to correct NASH treatment in the hospital of 
Ukraine, as 18% of funds were spent on minor drugs which are not represented 
the NDF of Ukraine.
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Objectives: To review clinical guidelines, recent HTA decisions, and the influ-
ence of economic analyses in HTA decisions related to biologic therapies in 
UC. MethOds: A literature review and targeted research provided information 
on clinical treatment guidelines (US and Europe) and HTAs (Europe) related to 
biologics in UC. Economic models in UC were identified and reviewed to deter-
mine how these affected HTA decisions. Results: Since several biologics were 
approved after the last version of the US treatment guidelines, the US guidelines 
only address the use of infliximab for the treatment of moderate or severe UC. 
In the UK, NICE has recommended infliximab, adalimumab, and golimumab as 
possible treatments for adults with moderate to severe UC in whom conventional 
therapy hasn’t worked or isn’t suitable. A recent NICE HTA recommends vedoli-
zumab as an option for treating moderately to severely active UC in adults only 
if the company provides vedolizumab with the discount agreed in the patient 
access scheme. The Scottish Medicines Consortium (SMC) recommends vedoli-
zumab for the treatment of adult patients with moderate-to-severe UC and an 
inadequate response, lost response, or intolerance to conventional therapy or a 
TNFα antagonist; this advice is “contingent upon the continuing availability of the 
patient access scheme in NHS Scotland or a list price that is equivalent or lower.” 
Earlier SMC advice did not recommend adalimumab, golimumab or infliximab 
for use within NHS Scotland due to lack of robust economic analyses. The SMC 
advice is superseded by the NICE HTA decisions. cOnclusiOns: In the UK and 
Scotland, more than 9 HTA have been performed in the 10 years since biologics 
have become available for the treatment of moderate-to-severe UC. Differential 
cost-effectiveness among specific indications, lines of treatment, and countries 
have resulted in a variety of recommendations as to their use which supplement 
clinical guidelines in UC.
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Objectives: The objective of this study was to describe the real-world use of 
adalimumab (ADA) for maintenance treatment of ulcerative colitis (UC) on a 
national level in Sweden. MethOds: A longitudinal, retrospective cohort study 
was conducted using the National Drug Registry and the National Patient Registry. 
UC patients (age ≥ 18 years) treated with ADA were included. Two cohorts were 
selected: (1) ADA naïve patients and (2) a cross-sectional cohort. Both cohorts were 
followed for a 12-month period. Dose escalation among the ADA naïve patients 
was defined as doubling of dose (ADA 40 mg every week) or having two follow-
ing filled prescriptions with average biweekly dose (ABD) ≥ 50 mg. Dosing in the 
cross-sectional cohort was assessed studying annual number of injections dis-
pensed among patients on maintenance treatment. Results: Five hundred and 
eighty-seven patients were identified as ADA naive during Jan 2010-April 2014. 
Dose-escalation by doubling of dose was observed in 273 (46.5%) patients with 
the median time to dose escalation being 84 days. Further analysis revealed that 
191 patients (32.5%) in the ADA naive patient cohort dose-escalated defined as 
(ABD) ≥ 50 mg, and of these 40 (20.9%) had a subsequent dose de-escalation which 
occurred after a median time of 162 days. In total 992 UC patients were identified 
in the cross-sectional cohort, defined as filling at least one prescription during May 
2013-April 2014, and of these 364 (37%) were on maintenance treatment. Out of the 
364 patients on maintenance treatment dispensing at least 22 injections during 
the period 140 (38%) received 30 injections or more. cOnclusiOns: This study 
demonstrates that UC patients receiving ADA in general have a patchy prescrip-
tion pattern, and that the proportion of patients who dose escalate is high. This 
finding and the impact that dose escalation has on costs may have implications 
for healthcare professionals and budget holders.
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Objectives: The purpose of this study is to assess the impact on physician pre-
scription behaviors of an outpatient prescription incentive program providing 
financial rewards to primary care physicians for saving prescription costs imple-
mented in October 2010 in South Korea. MethOds: A 10% sample of clinics 
(N= 1,625) was randomly selected from the entire clinics in the National Health 
Insurance claims database for the years 2009~2012, and all claims with the primary 
diagnosis of peptic ulcer or gastro-esophageal reflux diseases were extracted from 
those clinics’ data. We used a clinic-level random effects model analyzing policy 
effects on drug expenditures and prescribing behaviors including prescription rate 
of medicines treating target diseases, number of drug prescribed per claim, prescrip-
tion duration per claim. We also performed subgroup analyses by selected clinic 
characteristics, including practice type, size and specialty. Results: We found no 
significant impact of the program on drug expenditure overall. Prescription rate 
of target medicines increased and the average prescription duration per claim 
decreased after the incentive program. After the financial incentive program, clin-
ics in general medicine showed a lower prescription rate (by 0.8 percentage points), 
lower number of medicines prescribed (by 0.02), a lower prescription duration (by 
0.15 days), and lower drug expenditure per claim after the policy (by 740 won). Small 
clinics had shorter prescription duration (by 0.76 days), while large clinics and clinics 
in group practice had a higher prescription rate (by 1.5 and 2.5 percentage points, 
respectively) and higher number of medicines prescribed (by 0.03 for group practice 
only) after the program. cOnclusiOns: The financial incentive program worked as 
intended only in certain subgroup clinics for the target medicines. The reduction in 
prescription duration and the number of prescribed medicines in target claims in 
selected subgroups imply some margin for prescription adjustments.
quality of clinical evidence originating from same studies has been rated differ-
entially by different agencies. The economic evidence in this area was primarily 
based on cost-effectiveness/cost utility analysis (CEA/CUA), comprising ~95% of 
studies (time horizon 50 years to lifetime). The incremental cost-effectiveness 
ratios (ICER) ranged USD15000-200000 in PBAC, USD1246-376723 in NICE, USD750-
45200 in SMC, and USD11000-75000 in CADTH. More than 90% of the decisions 
based on ICER values were positive, with restriction being focused on cost negotia-
tions. The primary driver of positive decisions was majorly economic analysis in 
NICE, PBAC, and SMC, while clinical evidence drove positive recommendations in 
CADTH, IQWiG, and HAS. cOnclusiOns: Current landscape of CHC treatments 
in Canada, Australia, UK, Scotland, Germany, and France is majorly dominated 
by positive recommendations, considering the high unmet in this area. Most of 
the restrictions were around cost negotiations. The drivers of decisions fit with 
agency priorities, with economic analysis being the key driver in agencies with 
pharmacoeconomic analysis, and clinical evidence in agencies without pharma-
coeconomic analysis.
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Objectives: To compare the regulatory label indications and health technology 
assessment (HTA) recommendations for therapies indicated for the treatment of 
chronic hepatitis-C (CHC). MethOds: We reviewed the regulatory labels approved 
by European Medicines Agency (Europe), Health Canada (Canada) and Therapeutic 
Goods Administration (Australia). HTA reports for CHC therapies published by 
NICE (England and Wales), SMC (Scotland), HAS (France), IQWiG (Germany), CADTH 
(Canada) and PBAC (Australia) were assessed. Therapies with a positive HTA deci-
sion (recommended or restricted) were included in the analysis. Indication was 
split into four categories: age of the population (children, adults or both), fibrosis 
status (cirrhotic or non-cirrhotic), genotype, and prior treatment history (naïve or 
treatment-experienced). A match was defined as overlap of HTA and regulatory 
decision for any of the categories. Percentage correlation of the HTA indication 
with the regulatory label was calculated as the ratio of actual matches to the 
maximum possible matches for the parameters considered. Results: A total 
of 34 regulatory approvals and 48 HTA reports were identified from the public 
domain. Forty-six HTA reports providing a positive decision were included. Overall, 
HTA decisions correlated well with the marketing authorization (89%), with the 
highest correlation observed for CADTH and PBAC (100% each), followed by HAS 
(98%), NICE and SMC (86% each) and IQWiG (63%). Across agencies, highest cor-
relation was observed for age of the population (96% cases) and lowest for the 
prior treatment history (85% cases) of the population for whom the therapies were 
recommended. cOnclusiOns: Overall, the indication approved by HTA agency 
almost correlated completely with the indication granted marketing authoriza-
tion, except for NICE, SMC and IQWiG, indicating difference in agency priorities 
driving HTA decisions. Analyzing the population restriction applied by NICE, SMC 
and IQWiG would provide the decision drivers, allowing manufacturers to address 
these concerns in prospective submissions.
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Objectives: Recent advances in the management of hepatitis C virus (HCV) have 
yielded therapeutic modalities that are more efficacious, better tolerated, and have 
a lower pill and injection burden. Given the large population affected by HCV, deci-
sions by health technology assessment (HTA) bodies weigh significantly in terms 
of societal benefits and expenditures. The objective of this analysis was to evaluate 
recent patterns in HCV-related HTA decisions in selected countries. MethOds: 
HTA surveillance was conducted for Australia, Canada, France, Germany, and the 
United Kingdom (UK) from January 1, 2012 to June 1, 2015 (42 months). HTAs for 
HCV treatments were evaluated by genotype, decision, and decision rationale. 
Decisions were categorized as favorable, unfavorable, mixed (both favorable and 
unfavorable), and neutral (deferral). Results: 32 HCV-related HTAs were pub-
lished in the study time frame, with 7 assessments currently in development. 
Among the completed assessments, the majority of decisions were favorable (24, 
75%), with only 2 (6%) unfavorable and 6 (19%) mixed decisions. The most com-
mon rationales provided for a negative decision included insufficient data and/
or inappropriate comparators (4), insufficient benefit to justify the high cost (ie, 
improperly high incremental cost-effectiveness ratio [ICER]) (3), and inadequate 
clinical benefit vs the most appropriate comparator (1). France and Canada had 
the highest percentage of favorable decisions (5 of 5 and 9 of 9, respectively, 
100%), followed by the UK (3 of 4, 75%), Australia (5 of 8, 63%), and Germany (2 
of 6, 33%). cOnclusiOns: Based on the last 42 months of HCV-related HTAs, 
75% of decisions were favorable. However, the most significant factors leading to 
unfavorable assessments for HCV products are related to the inability to supply 
advantageous clinical and cost-effectiveness data. This analysis suggests that 
manufacturers would have greater success with HTA decisions if more robust 
health economic and clinical data are generated.
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